A new path to the cancer epigenome.
Department of Cancer Biology and Therapeutics, Merck Research Laboratories, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. victoria_richon@merck.com
Victoria M
VM
Richon
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D002460:Cell Line; D045744:Cell Line, Tumor; D016764:Cell Polarity; D002874:Chromosome Mapping; D018450:Disease Progression; D044127:Epigenesis, Genetic / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D036961:Matrix Attachment Region Binding Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D009368:Neoplasm Transplantation; D010641:Phenotype; D011379:Prognosis; D034622:RNA Interference
D014408:Biomarkers, Tumor; D036961:Matrix Attachment Region Binding Proteins; C076189:SATB1 protein, human